ウェビナー動画：Merck EMD社、医薬品候補選定のDMTAサイクルを加速するデータワークフローの自動化
Merck社では、完全に自動化されたデータワークフローを構築することで、HTSやHit-to-Leadの取り組みを効率化し、DMTAサイクル全体において迅速な意思決定を実現しています。統合データエコシステムにより、AI/MLによる候補化合物の優先順位付け、データ品質の確保、トレーサビリティの強化が可能になりました。
In this webinar, learn how Merck Healthcare is accelerating drug discovery by building an integrated data ecosystem using the Genedata platform to streamline workflows, reduces cycle times, and enables AI/ML-driven decision-making.
Bolek Zapiec, Director, Head of Digital & Data Science at Merck, will share how their Discovery Pharmacology team implemented a fully automated data workflow using Genedata Screener. This end-to-end solution — from data load through QC and reporting — supports high-throughput screening (HTS) and Hit-to-Lead activities, enabling faster, more informed decisions across the DMTA (Design-Make-Test-Analyze) cycle.
Learn how Merck uses Genedata to:
- Accelerate DMTA cycles by automating data processing and analysis.
- Integrate multi-modal data to support AI/ML-driven candidate prioritization.
- Streamline data flows across Discovery Pharmacology labs.
- Ensure data quality, consistency, and traceability across the pipeline.
- Reduce manual effort and cycle times through end-to-end workflow automation.
Who Should Watch:
- Discovery Scientists & HTS Specialists: Learn how automation accelerates hit identification and validation.
- Data Scientists & AI/ML Teams: See how integrated data ecosystems enable predictive modeling and candidate ranking.
- IT & Digital Transformation Leaders: Explore scalable, automated solutions for data management in drug discovery.
- Research and Development Managers: Understand how workflow automation improves efficiency and decision-making.
- Biopharma Executives: Gain insights into how automation and data integration drive innovation and operational efficiency in early drug discovery.